Drug intelligence / Profile preview

NB007

Development stage: Preclinical
Lead developer: Ningbo Newbay Medical Technology
Modality: Small Molecules

Overview

NB007 is a preclinical-stage small molecule therapeutic being developed by Ningbo Newbay Medical Technology (Newbay Pharma) for the treatment of advanced solid tumors. As of early 2024, the specific biological target of NB007 has not been publicly disclosed by the developer. The compound is part of Newbay Pharma's oncology pipeline, which focuses on developing targeted small molecule inhibitors for cancer.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on NB007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB007.

Explore the full profile